The incidence of CNS bleeds during the 28-day study period was 6 (0.5%) and 5 (0.4%) for drotrecogin alfa (activated)-treated and placebo-treated patients, respectively.
KNS verejooksude esinemissagedus 28- päevase uuringuperioodi jooksul oli (aktiveeritud) α- drotrekogiini puhul 6 (0, 5%) ja platseebo puhul 5 (0, 4%).